A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Ji, Sang Hoon ^a   Lim, Do Hyoung ^a   Yi, Seong Yoon ^a   Kim, Hyo Song ^a   Jun, Hyun Jung ^a   Kim, Kyoung Ha ^a   Chang, Myung Hee ^a   Park, Min Jae ^a   Uhm, Ji Eun ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; STOMACH TUMOR; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449136705     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-110     Document Type: Article

References (17)

1. Bae JM Won YJ Jung KW Park JG Annual report of the Korean central cancer registry program 2000 Cancer Res Treat 2002, 34:77-83.
2. Pyrhonen S Kuitunen T Nyandoto P Kouri M Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 1995, 71(3):587-591. 7533517
3. Glimelius B Ekstrom K Hoffman K Graf W Sjoden PO Haglund U Svensson C Enander LK Linne T Sellstrom H et al Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 1997, 8(2):163-168. 10.1023/ A:1008243606668 9093725
4. Van Cutsem E Haller D Ohtsu A The role of chemotherapy in the current treatment of gastric cancer Gastric Cancer 2002, 5(Suppl 1):17-22. 10.1007/s10120-002-0219-y 12772882
5. Park SH Kang WK Lee HR Park J Lee KE Lee SH Park JO Kim K Kim WS Chung CW et al Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen Am J Clin Oncol 2004, 27(5):477-480. 10.1097/ 01.coc.0000136018.81814.79 15596914
6. Park SH Choi EY Bang SM Cho EK Lee JH Shin DB Ki Lee W Chung M Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes Anticancer Drugs 2005, 16(6):621-625. 10.1097/00001813-200507000-00005 15930889
7. Park SH Kim YS Hong J Park J Nam E Cho EK Shin DB Lee JH Lee WK Chung M Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: A noncomparative phase II study Anticancer Drugs 2008, 19(3):303-307. 10.1097/CAD.0b013e3282f46ad8 18510177
8. Wilson D Hiller L Geh JI Review of second-line chemotherapy for advanced gastric adenocarcinoma Clin Oncol (R Coll Radiol) 2005, 17(2):81-90. 15830569
9. Lee J Lim T Uhm J Park K Park S Lee S Park J Park Y Lim H Sohn T et al Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann Oncol 2007, 18(5):886-891. 10.1093/annonc/mdl501 17298958
10. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC et al New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205 10655437
11. Park SH Lee WK Chung M Bang SM Cho EK Lee JH Shin DB Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy Cancer Chemother Pharmacol 2006, 57(3):289-294. 10.1007/ s00280-005-0055-y 16010588
12. Chau I Norman AR Cunningham D Waters JS Oates J Ross PJ Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 2004, 22(12):2395-2403. 10.1200/JCO.2004.08.154 15197201
13. Park SH Lee J Lee SH Park JO Kim K Kim WS Jung CW Park YS Kang WK Park K et al Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Cancer Chemother Pharmacol 2006, 57(1):91-96. 10.1007/ s00280-005-0027-2 16088407
14. Galizia G Lieto E Orditura M Castellano P Mura AL Imperatore V Pinto M Zamboli A De Vita F Ferraraccio F Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery World journal of surgery 2007, 31(7):1458-1468. 10.1007/s00268-007-9016-4 17516110
15. Lieto E Ferraraccio F Orditura M Castellano P Mura AL Pinto M Zamboli A De Vita F Galizia G Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients Annals of surgical oncology 2008, 15(1):69-79. 10.1245/s10434-007-9596-0 17896140
16. Park DI Yun JW Park JH Oh SJ Kim HJ Cho YK Sohn CI Jeon WK Kim BI Yoo CH et al HER-2/neu amplification is an independent prognostic factor in gastric cancer Digestive diseases and sciences 2006, 51(8):1371-1379. 10.1007/s10620-005-9057-1
17. Matsubara J Nishina T Yamada Y Moriwaki T Shimoda T Kajiwara T Nakajima TE Kato K Hamaguchi T Shimada Y et al Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer Br J Cancer 2008, 98(4):832-839. 10.1038/ sj.bjc.6604211 18231104